Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination. The high-dose vaccine is four times more concentrated than the standard Fluzone vaccine, hence providing a higher antibody response. Fluzone HD was approved for use in persons aged ≥65 years in the US in December 2009.
The superior efficacy of Fluzone High-Dose (HD) (inactivated split virion trivalent influenza vaccine [TIV]; Sanofi Pasteur) compared to standard-dose inactivated influenza vaccines (IIVs) has positioned it as one of the preferred options for the elderly in the US.
LIST OF TABLES
6 Table 1: Fluzone High-Dose drug profile
6 Table 2: Approval history of Fluzone HD for seasonal influenza vaccination
8 Table 3: Late-phase trials of Fluzone HD for seasonal influenza vaccination
9 Table 4: Fluzone High-Dose for seasonal influenza – SWOT analysis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.